Abstract: Disclosed herein, in certain embodiments, are recombinant myxoma viruses (MYXVs) and nucleic acid constructs encoding the recombinant MYXVs. In some embodiments, the MYXVs are engineered to inactivate or attenuate an activity or expression level of an M153 protein. In some embodiments, the MYXVs are engineered to express one or more transgenes such as a tumor necrosis factor (TNF), interleukin-12 (IL-12), or decorin. Also disclosed herein, in certain embodiments, are methods of using the MYXVs. Some embodiments include providing a MYXV as described herein to a subject in need thereof.
Type:
Grant
Filed:
September 2, 2020
Date of Patent:
September 14, 2021
Assignees:
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, ONCOMYX THERAPEUTICS, INC.
Inventors:
Douglas Grant McFadden, Mohammed Masmudur Rahman, Nancy Villa, Lino Torres-Dominguez, Lina Franco Achury, Leslie Lynne Sharp